Alkahest Scientific Founder Tony Wyss-Coray Recognized as One of TIME Magazine’s 50 Most Influential People in Health Care
November 2, 2018
SAN CARLOS, Calif., — Alkahest Inc. (“Alkahest”), a clinical-stage biotechnology company focused on developing innovative therapies to treat age-related diseases, announced today that Tony Wyss-Coray Ph.D., Alkahest’s co-founder and board member was named to TIME Health’s list of individuals who were most influential in transforming healthcare in 2018.
“Time Magazine’s ‘Health Care 50’ highlights those who have significantly changed the state of U.S. health care this year and we are pleased to see this recognition for Tony’s pioneering work in understanding the role of the plasma proteome in age-related diseases,” said Karoly Nikolich, Ph.D., Alkahest’s co-founder and chief executive officer.
Professor Wyss-Coray received his Ph.D. from the University of Berne, Switzerland and joined Stanford University’sfaculty in 2002, where he now serves as a professor of neurology and neurological sciences. He is also the co-director of Stanford Alzheimer’s Disease Research Center and associate director of the Center for Tissue Regeneration, Repair and Restoration at the Palo Alto VA. His lab investigates the role of immune responses in brain aging and neurodegeneration with a focus on cognitive decline and Alzheimer’s disease. Together with Dr. Karoly Nikolich, Professor Wyss-Coray established Alkahest in 2014 to translate his pioneering research into innovative medicines that can help patients with age-related diseases.
Alkahest is a privately-held clinical-stage company based in the San Francisco Bay Area developing treatments for age-related diseases, with an emphasis on neurodegeneration — a key medical challenge for our generation. The company’s breakthrough research has elucidated changes in the plasma proteome in healthy aging and age-related diseases, and demonstrated that factors in the blood plasma can be augmented or inhibited in order to reverse detrimental effects of aging in both normal aging and disease models in animals. Alkahest is developing novel plasma-based therapies in collaboration with Barcelona, Spain-based Grifols, a global healthcare company and leading producer of plasma therapies. For further information see www.alkahest.com.
Vice President Business Development
LifeSci Public Relations